Point72 Asset Management
ITCI

Point72 Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Point72 Asset Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-251,823
Closed -$21M – 2660
2024
Q4 		$21M Buy
251,823
+131,961
+110% +$10.8M 0.05% 426
2024
Q3 		$8.77M Sell
119,862
-434,324
-78% -$32.6M 0.02% 684
2024
Q2 		$38M Buy
554,186
+380,420
+219% +$26.4M 0.1% 267
2024
Q1 		$12M Buy
+173,766
New +$11.9M 0.03% 648
2023
Q3 		– Sell
-25,121
Closed -$1.59M – 2942
2023
Q2 		$1.59M Sell
25,121
-209,008
-89% -$13M ﹤0.01% 1075
2023
Q1 		$12.7M Buy
234,129
+39,977
+21% +$1.93M 0.04% 482
2022
Q4 		$10.3M Sell
194,152
-461,648
-70% -$23.1M 0.03% 542
2022
Q3 		$30.5M Buy
+655,800
New +$34.3M 0.12% 225
2020
Q4 		– Sell
-555,643
Closed -$14.3M – 1180
2020
Q3 		$14.3M Buy
+555,643
New +$12.7M 0.07% 335
2019
Q4 		– Sell
-559,900
Closed -$4.18M – 1311
2019
Q3 		$4.18M Buy
+559,900
New +$5.37M 0.03% 490
2019
Q1 		– Sell
-300,352
Closed -$3.84M – 1276
2018
Q4 		$3.42M Sell
300,352
-334,114
-53% -$5.39M 0.02% 630
2018
Q3 		$13.8M Buy
634,466
+444,609
+234% +$9.3M 0.06% 392
2018
Q2 		$3.35M Sell
189,857
-40,637
-18% -$825K 0.01% 688
2018
Q1 		$4.85M Sell
230,494
-219,506
-49% -$4.28M 0.02% 580
2017
Q4 		$6.52M Buy
450,000
+189,300
+73% +$2.92M 0.03% 540
2017
Q3 		$4.11M Buy
+260,700
New +$3.83M 0.02% 575
2016
Q4 		– Sell
-153,300
Closed -$2.34M – 860
2016
Q3 		$2.34M Sell
153,300
-16,000
-9% -$647K 0.02% 541
2016
Q2 		$6.57M Sell
169,300
-61,300
-27% -$2.2M 0.04% 373
2016
Q1 		$6.41M Buy
230,600
+66,400
+40% +$2.21M 0.05% 383
2015
Q4 		$8.83M Buy
164,200
+139,900
+576% +$7.06M 0.07% 315
2015
Q3 		$973K Sell
24,300
-89,800
-79% -$2.93M 0.01% 620
2015
Q2 		$3.65M Buy
114,100
+24,277
+27% +$616K 0.03% 495
2015
Q1 		$2.15M Buy
+89,823
New +$2.01M 0.01% 552

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Point72 Asset Management's ITCI Position: Q1 2025 in Review

Point72 Asset Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 251,823 shares — an estimated $21M sold.

Point72 Asset Management first reported a position in ITCI in Q1 2015 and held it in 23 quarters. The position peaked at $38M in Q2 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Point72 Asset Management reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Point72 Asset Management sold 251,823 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $21M.
  • Point72 Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2015 and held it in 23 quarters.
  • Point72 Asset Management's Intra-Cellular Therapies Inc. position peaked at $38M in Q2 2024.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Point72 Asset Management's 13F filing for Q1 2025, filed 15 May 2025.